- Yvanka Gilliam brings a wealth of industry experience to the company, having worked in pharma for more than 20 years
- Prior to Diaceutics, she had roles in Kantar Health, IQVIA Asia Pacific and AstraZeneca
- Yvanka will be responsible for managing business development and operations in the APAC region
- Yvanka’s role will also include identifying innovative and creative services and solutions to help leverage the Diaceutics’ DXRX platform
Diaceutics PLC, (AIM: DXRX), today announces the appointment of Yvanka Gilliam as Vice President of Operations, Asia Pacific (APAC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005504/en/
Newly-appointed Diaceutics VP of Operations, APAC, Yvanka Gilliam. (Photo: Business Wire)
In her new role, Yvanka will be responsible for managing business development and operations within the APAC region with a core focus on establishing key collaborations and strategic partnerships to drive growth and revenue. Her role will also include identifying innovative and creative services and solutions to help leverage the company’s platform, DXRX, and increase the offering.
Yvanka has a strong track record managing the delivery of real-world insights for evaluation by regulators, payers and clinicians. Prior to joining Diaceutics, Yvanka worked with Kantar Health as a Senior Client Partner, Real World Evidence, where she developed and implemented global business planning strategies and conducted high-quality research. In recent years, Yvanka has also worked with IQVIA Asia Pacific in the Real World Insights Division and as a Senior Medical Science Liaison at AstraZeneca Pharmaceutical Corporation.
Yvanka holds a doctorate degree in Pharmacy from The University of Michigan College of Pharmacy in Ann Arbor, a bachelor’s degree in Biology and Chemistry from Grambling University in Louisiana and an MBA in International Business from Rutgers University Singapore. Yvanka’s work has been published in the Annals of Oncology and the Journal of Clinical Oncology – an American Society of Clinical Oncology (ASCO) Journal.
Peter Keeling, Chief Executive Officer of Diaceutics, said:“Yvanka’s appointment will strengthen Diaceutics’ credentials as the market leader in the development and commercialization of precision medicine diagnostics. As her 20-plus year career in pharma has been focused primarily on the Research and Development of innovative oncology compounds, Yvanka is firmly aligned with Diaceutics’ goal to bridge the gap between diagnostics and therapeutic decision-making in order to improve testing outcomes for patients and enable better access to the right drug at the right time.”
Yvanka Gilliam, Diaceutics VP of Operations, APAC, said: “I’m delighted to join Diaceutics, a company that I have long admired for their unwavering commitment to drive better testing and better treatment for patients. I look forward to broadening Diaceutics’ influence in the APAC region and working alongside a team of driven and talented individuals. I’m particularly excited to come on board as the company’s DXRX – The Diagnostic Network® platform continues to gain traction within the industry, as we help get every patient the treatment they deserve.”
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX – the world’s first diagnostic network for precision medicine. Diaceutics has worked on every precision medicine brought to market and provides services to36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.